Related Experiment Video
Updated: Jun 1, 2026
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
From cell biology to therapy: ENMD-2076 in the treatment of multiple myeloma
Shuhong Zhang1, Sherif S Farag
1Indiana University School of Medicine, Division of Hematology and Oncology, Department of Medicine, Indianapolis, IN 46202, USA.
Introduction:
Multiple myeloma (MM) remains incurable, indicating the need for continued investigation of innovative strategies. Recent progress in molecular biology has advanced the discovery of novel drugs for MM. ENMD-2076 is an orally bioavailable, multi-target kinase inhibitor with multiple mechanisms of action, including anti-proliferative and pro-apoptotic activity, and anti-angiogenic effects.
Areas Covered:
In this review, the authors summarize the preclinical in vitro and in vivo data that have formed the rationale for clinical investigation of ENMD-2076 in MM. In addition, the authors review the early clinical results of ENMD-2076 in MM and other malignancies, and speculate on potential avenues of future clinical research in the development of this drug for MM.
Expert Opinion:
There is a strong preclinical rationale for investigating ENMD-2076 in MM that is confirmed by early clinical results in an ongoing Phase I trial in patients with relapsed or refractory MM. Optimal strategies for developing ENMD-2076 in MM will require better elucidation of its mechanism of action, investigation of biomarkers for response and development of rationale synergistic combinations with other active agents.
Insights
ENMD-2076, a novel multi-target kinase inhibitor, shows promise for treating multiple myeloma (MM). Early clinical trials confirm its preclinical efficacy, suggesting a new therapeutic avenue for this incurable cancer.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Multiple myeloma (MM) is an incurable hematologic malignancy.
- Novel therapeutic strategies are crucial for improving MM treatment outcomes.
- ENMD-2076 is an orally bioavailable multi-target kinase inhibitor with demonstrated anti-cancer properties.
Purpose of the Study:
- To review preclinical data supporting the clinical investigation of ENMD-2076 in MM.
- To summarize early clinical findings of ENMD-2076 in MM and other cancers.
- To explore future research directions for ENMD-2076 in MM treatment.
Main Methods:
- Review of preclinical in vitro and in vivo studies.
- Analysis of early-phase clinical trial data for ENMD-2076.
- Synthesis of existing literature on ENMD-2076's mechanism of action and clinical activity.
Main Results:
- Strong preclinical rationale exists for ENMD-2076 in MM.
- Early clinical results from an ongoing Phase I trial in relapsed/refractory MM are encouraging.
- ENMD-2076 exhibits anti-proliferative, pro-apoptotic, and anti-angiogenic effects.
Conclusions:
- ENMD-2076 demonstrates potential as a novel therapeutic agent for MM.
- Further research is needed to optimize ENMD-2076 development strategies.
- Elucidating mechanisms, identifying biomarkers, and exploring combinations are key for future MM treatment.
More Related Videos
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:38Mitogens and the Cell Cycle